Safety and Tolerability of Varenicline in Schizophrenia (SATOVA)

NCT ID: NCT00702793

Last Updated: 2017-11-29

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE4
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-04-30
• Study Completion Date: 2012-05-31

Brief Summary

This is a 15 week trial to determine (1) the safety and tolerability of varenicline when used for smoking cessation/reduction in individuals with schizophrenia; (2) if treatment with varenicline affects the symptoms of schizophrenia.

Detailed Description

Researchers are looking to recruit a total of 50 subjects at Riverview and Forensic Psychiatric Hospitals who would like to reduce or quit smoking cigarettes. This open label pilot study will gather information regarding the safety and tolerability of varenicline in subjects who have been diagnosed with schizophrenia or schizoaffective disorder. Consenting subjects will be prescribed varenicline as follows: varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily through week 12. The research team will meet with the subject once a week for twelve weeks and the subject will be interviewed and asked to complete questionnaires about his/her psychiatric symptoms, tobacco use and nicotine dependence. The measures used include the FTND, PANSS, CGI-I, CGI-S, ESRS, UKU, BARS, WSWS, QSU-brief, mCEQ, and the OAS-M. The CGI-SS will also be completed throughout the study as well as once weekly for three weeks following the completion of the study (Post-Study follow-up visits 1-3).

Conditions

Schizophrenia; Schizoaffective; Psychosis

Keywords

Smoking cessation; schizophrenia; schizoaffective; psychosis; varenicline; champix; chantix; nicotine dependence

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

Smoking cessation drug - varenicline

Group Type: EXPERIMENTAL

Varenicline

Intervention Type: DRUG

Varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily through week 12. Administration of twice daily dosing should be at least 8 hours apart.

Interventions

Varenicline

Varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily through week 12. Administration of twice daily dosing should be at least 8 hours apart.

Intervention Type: DRUG

Other Intervention Names

Champix; Chantix

Eligibility Criteria

Inclusion Criteria

• Inpatients with a diagnosis of schizophrenia or schizoaffective disorder
• Individuals between the ages of 19 and 65 years of age
• Individuals that had smoked 10 cigarette/day or more during the previous year, and had no period of smoking abstinence longer than 3 months in the past year
• Individuals that are not expected to be discharged from hospital within 4 months.

Exclusion Criteria

• Clinically significant allergic reactions to the study medication
• Clinically significant abnormalities in the screening laboratory values
• Subjects at significant risk of self-harm
• Previous treatment with varenicline
• Women who are pregnant, breast-feeding, or of child-bearing potential not using adequate contraception
• Men not using adequate contraception
• Use of medications that might interfere with the study medication evaluation

• Nicotine replacement
• Nortriptyline
• Clonidine

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Provincial Health Services Authority

OTHER

Sponsor Role: collaborator

University of British Columbia

OTHER

Sponsor Role: lead

Responsible Party

Ric Procyshyn

Principle Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Ric M. Procyshyn, Ph.D

Role: PRINCIPAL_INVESTIGATOR

University of British Columbia

Alasdair Barr, Ph.D

Role: STUDY_DIRECTOR

University of British Columbia

Joyce Coutts, MD

Role: STUDY_DIRECTOR

Forensic Psychiatric Institute

Sean Flynn, MD

Role: STUDY_DIRECTOR

University of British Columbia

Chris Schenk, MD

Role: STUDY_DIRECTOR

Riverview Hospital

William Honer, MD

Role: STUDY_DIRECTOR

University of British Columbia

Countries

Canada

Other Identifiers

H07-02939

Identifier Type: -

Identifier Source: org_study_id